Prostate cancer (PC) is the most common type of cancer in men and one of the main causes of death in developed countries of Europe and North America [1]. The incidence of it has risen annually by 3% since 2014 [2]. Prostate cancer is the second-leading cause of death among males in the US. According to the American Cancer Society [3], about 1 in 44 men will die of prostate cancer [4]. The pathology is not always diagnosed, characterized by a latent course, which may be a reason why more of the advanced forms of prostate cancer are found at late stages in the present days. Therefore, it is crucial to be aware of all stage 4 prostate cancer treatment options.
Standard Treatment for Stage 4 Prostate Cancer
Selecting the treatment for metastatic adenocarcinoma in prostate often depends on factors like the extent of metastasis, prior treatments, and the patient’s personal preferences. There are several treatment strategies, that are considered to be the standard of treatment for 4th stage prostate cancer, including hormones, radio- and chemotherapy, immunotherapy, targeted therapy, and surgery [5].
Hormonal therapy is the basis of locally advanced and metastatic prostate adenocarcinoma treatment. It is a systemic type of treatment, which is aimed at blocking the synthesis of male hormones (androgens) since they facilitate tumor growth. Hormonal therapy controls disease progression in about 70–85% of advanced cases temporarily. Biomarker identification can guide personalized treatment plans, which is a reason it is recommended to be done prior to selecting a management strategy.
Chemotherapy is another systemic treatment modality that is used for advanced prostate cancer management. Typically, 6 to 10 cycles of chemotherapy have to be performed in order to reach effect. It is also more beneficial for patients with hormone-resistant and metastatic cancer, especially when combined with other interventions (radio- andor immunotherapy).
Radiotherapy is a standard therapy for recurrent and advanced adenocarcinoma of the prostate. It is typically administered alongside hormone therapy (for hormone-sensitive tumors) and chemotherapy (so-called triplet systemic therapy). If a tumor is resistant to previous treatment options, radiopharmaceuticals can be applied such as Radium-223. Radium-223 is typically prescribed for advanced prostate cancer, which has already metastasized to the bones. Radium-223 delivers radiation directly to bone metastases, minimizing damage to healthy tissue. It is commonly administered in combination with androgen deprivation therapy (hormones) andor chemotherapy.
Targeted therapy is the first-line treatment of metastatic prostate cancer alongside other treatment modalities. These drugs target specific proteins on the surface of malignant cells, which are responsible for cancer cell’s growth and nutrition. Targeted therapy statistically improves progression-free survival in patients with metastatic castration-resistant cancer. When used in combination with hormone therapy, it can lead to a significant reduction of PSA levels, improved survival rates, and better disease control.
These methods are combined for the management of metastatic cancer to provide maximum eradication and disease control. Unfortunately, conventional methods like chemotherapy, hormonal therapy, and radiation often come with side effects and lower tolerance, especially in advanced stages. Therefore, other novel therapeutic modalities are emerging: dendritic cell therapy, chemoembolization, and treatment with Actinium and Lutetium. They demonstrate better tolerability and fewer adverse effects.
New Treatment Methods for Stage 4 Prostate Cancer
Interventional Radiology for Stage 4 Prostate Cancer
Interventional radiology has several minimally invasive procedures for advanced prostate cancer adenocarcinoma. What is important, interventions reduce damage to healthy tissues. They are typically performed percutaneously using specialized instruments – under real-time imaging guidance such as ultrasound or computed tomography (CT). Modern clinical practice employs various interventional modalities, each of which has advantages in managing different prostate cancer cases.
Thermal ablation is one of the primary forms of ablation, which employs high temperatures to destroy tumor cells. Among the most well-researched modalities in this category are high-intensity focused ultrasound (HIFU), which delivers concentrated ultrasound energy, and laser interstitial thermal therapy (LITT), which focuses laser energy on tumor foci. Originally indicated for benign prostatic hyperplasia (BPH) and locally advanced prostate cancer, thermal ablation has become relevant in managing stage 4 prostate adenocarcinoma, especially in cases of recurrence after radiation therapy (RT).
Cryoablation is another ablation energy-based therapeutic modality utilizing freezing to cause cellular death in tumors. In the context of advanced prostate cancer management, it proved to have promising outcomes, such as a considerable reduction in prostate-specific antigen (PSA) levels. The post-treatment investigation also shows stable prostate volumes and clinically valid local tumor suppression. In addition, cryoablation is associated with a low number of side effects presenting it as a patient-friendly cancer treatment modality.
Electrochemotherapy (ECT) utilizes targeted electrical current alongside the administration of chemotherapeutic agents in the form of an injection, which results in maximizing tumor cell elimination. This method has shown particular efficacy in treating large tumors, particularly those in anatomically crucial or surgically inaccessible areas (near vital structures). Furthermore, ECT contributes to immune response activation, resulting in additional therapeutic value when accompanying immunotherapy in metastatic prostate cancer management.
Electrochemotherapy vs Traditional Ablation: What Makes ECT Different?
Chemoembolization is a localized, minimally invasive treatment, that delivers high concentrations of chemotherapy directly to the tumor and blocks its blood supply. During the procedure, a healthcare professional inserts a catheter into the blood vessel (typically in the groin). Under the visual guidance, he moves it closer to the tumor and, after reaching the target area, releases chemo drugs and blocking emboli. This approach is particularly effective for metastatic lesions in the liver or other localized areas.
Studies have shown that chemoembolization significantly reduces the size of metastatic foci and the size of the prostate. For stage 4 prostate cancer patients, this dual-action mechanism provides both tumor control and symptom relief. It is also extremely beneficial for the management of symptoms – gross hematuria or urinary retention as a result of lower urinary obstruction in patients with advanced prostate cancer. Chemoembolization minimizes systemic side effects while maximizing therapeutic impact at the tumor site.
To explore the steps of how the procedure is performed and the practical benefits of chemoembolization, we suggest you watch the interview with Professor Attila Kovács, who discusses what chemoembolization is, indications, and contraindications for this treatment.
Prostatic artery embolization (PAE) was initially indicated for benign prostatic hyperplasia. Later, it was discovered that PAE was relevant for advanced cancer management, especially where quality of life was a critical concern. This is a minimally invasive intervention.
PAE blocks selected prostatic arteries and thus reduces blood flow to the gland itself and metastatic lesions. It is valuable for patients with persistent lower urinary tract symptoms: urinary retention, nocturia, and incomplete bladder emptying. PAE helps control tumor-related symptoms and complications without additional medications burden.
*Data of Prof. Dr. med. Attila Kovács
As a supportive therapy in stage 4 prostate cancer management, PAE has demonstrated a favorable safety profile, minimal side effects. PAE addresses widespread complications – bleeding, pain, etc. It can be performed under local anesthesia, requires minimal recovery time, and provides rapid symptom relief – even when options are limited.
Prostate Embolization Before Radiation: Prof. Kovács on a Game-Changing Approach to Prostate Cancer
Immunotherapy with Dendritic Cells for Stage 4 Prostate Cancer
This therapy leverages the patient’s immune system by training. Dendritic cells are antigen-presenting cells that capture foreign antigens, analyze them, and mediate immune response while promoting tolerance to the self and harmless environment. As a result, dendritic cells can activate specific T-cells programmed for killing the pathogen expressing this specific antigen. Being a massive scientific breakthrough, it brought its discoverer (Ralph M. Steinman) a Nobel Prize in medicine [6]. Immunotherapy with dendritic cells offers a personalized approach, strengthening the body’s natural defense mechanisms.
Dendritic cell immunotherapy is particularly useful for advanced cancers such as 4th stage prostate cancer treatment or recurrent prostate cancer. Hormone-refractory and metastatic prostate cancers are also preferable candidates for immunotherapy with dendritic cells. Immunotherapy is commonly well-tolerated and has fewer side effects compared to standard treatment modalities.
To learn more about this promising treatment, watch an interview with Prof. Gansauge, who is delving into the latest advancements in cancer treatment and answering common patient questions.
Actinium Treatment for Stage 4 Prostate Cancer
Actinium-225 PSMA-617 is a novel award-winning type of radionuclide therapy for metastatic prostate cancer [7]. It targets a specific protein named PSMA, which is typically found on the surface of cancer cells in a remarkably high amount as compared to healthy prostate cells. PSMA-617 is a specific artificially created molecule, which searches for cancer cells expressing PSMA protein on their surface and connects with them.
Since PSMA-617 possesses an ability to carry radionuclides such as Actinium-225, by binding to cancer cell proteins, it enables targeted irradiation of these cells. By forming an extremely firm bond with PSMA antigens on the surface of cancer cells, Actinium-225 PSMA therapy grants a chance to eliminate even the most distant metastases. Owing to such characteristics, Actinium-225 PSMA-617 showed quite promising results in various studies in patients with metastatic castration-resistant prostate cancer (mCRPC), such as quite high treatment response rates, low toxicity, and overall pain reduction.
Treatment with Lutetium for Stage 4 Prostate Cancer
Lutetium-177 vipivotide tetraxetan is an innovative therapeutic agent designed for advanced metastatic prostate cancer, such as for PCa treatment stage 4. As a part of a new branch of medicine – theranostic medicine – this novel method combines diagnostic imaging with targeted radiation. As a result, this targeted radionuclide therapy delivers radiation specifically to prostate cancer cells expressing the Prostate-Specific Membrane Antigen (PSMA). Lutetium-177 is usually administered alongside its companion diagnostic substance gallium-68 gozetotide, which is used in PSMA PET imaging to accurately identify PSMA-positive cancer cells.
In order to understand this method better, we invite you to watch Dr. Stefan Dresel talking about how Lutetium-177 PSMA therapy works. Both the lutetium-177 PSMA therapy and the gallium-68 PSMA imaging received FDA approval, with clinical evidence demonstrating notable improvements in survival outcomes, quality of life, and delayed disease progression for prostate cancer patients. It is validated by inspiring stories from our patients as well. John Baker, who struggled with metastatic prostate cancer, went through several therapeutic modalities. Yet, when he found out about Lutetium-177, he decided to try it out. And it proved to be worthwhile. Watch his cancer management journey and find out more about his experience with Lutetium.
Clinics for Stage 4 Prostate Cancer treatment
Patients with advanced prostate cancer are increasingly considering treatment abroad, as large cancer centers offer a multidisciplinary approach, PSMA diagnostics, and advanced treatment methods. When choosing the best prostate cancer hospitals, men consider not only the results but also the cost of prostate cancer stage 4 treatment. In the case of metastases, the metastatic prostate cancer treatment cost is estimated separately – the full treatment cost for advanced prostate cancer depends on the chosen treatment method and other factors. Germany offers state-of-the-art care – here, stage 4 prostate cancer treatment in clinics provides access to advanced diagnostics and innovative therapies. In Germany, patients can access the transparent cost of stage 4 prostate cancer treatment with no hidden fees.
Best Hospitals for Stage 4 Prostate Cancer Treatment
| Rank | Clinic | Country | Key Strengths |
|---|---|---|---|
| 1 | University Hospital Munich | Germany | PSMA diagnostics, comprehensive approach, multidisciplinary team |
| 2 | University Hospital Ulm | Germany | Expertise in interventional radiology, PSMA therapy, advanced prostate cancer treatment |
| 3 | Urology Clinic Wiener Platz | Germany | Minimally invasive urology procedures, local therapy |
University Hospital Munich
The University Hospital Munich is considered one of the leading centers for urological oncology in Europe. Here, patients with stage 4 are offered individual regimens of hormonal, chemo- and PSMA-radioligand therapy, as well as palliative interventions to control symptoms. In complex cases, doctors explain in detail the prostate cancer stage 4 surgery cost if surgery is considered to alleviate the condition. The center is included in the list of best hospitals for stage 4 prostate cancer treatment, as it combines the scientific basis and advanced treatment methods. Much attention is paid to the quality of life and pain relief.
University Hospital Ulm
The University Hospital Ulm is recognized for its strong expertise in interventional radiology. The institution is often mentioned among the top hospitals for stage 4 prostate cancer treatment, as it treats a large number of patients with advanced cancer. Teams of urologists and oncologists work together, adjusting therapy when the course of the disease changes. Supportive treatment (aimed at controlling pain and complications of metastases) plays a significant role.
Urology Clinic Wiener Platz
The Urology Clinic Wiener Platz specializes in modern urology and minimally invasive interventions. Patients who need symptom control, local procedures, or a second opinion on systemic therapy come here. The clinic is considered one of the best hospitals for advanced prostate cancer due to its narrow specialization and personalized support. At the same time, the center cooperates with large oncology institutions. Wiener Platz is one of the most reliable stage 4 prostate cancer treatment hospitals for patients who value comfort, rapid treatment organization, and an individual approach.
Stage 4 Prostate Cancer Treatment Cost
| Treatment Method | Germany | Great Britain | USA |
|---|---|---|---|
| Standard Treatment | €80,000 - €150,000 full course | €90,000 - €165,000 full course | €100,000 - €180,000 full course |
| Innovative Methods | €25,000 - €60,000 full course | €70,000 - €120,000 full course | €100,000 - €150,000 full course |
Comparative Chart with the Effectiveness of the Listed Methods in Stage 4 Prostate Cancer
Research suggests that a multidisciplinary approach often yields the best results for patients with advanced stages of disease. Combining hormone therapy with chemotherapy or adding newer antiandrogenic drugs can extend survival and delay disease progression. Regular monitoring and adjustments to treatment for stage 4 prostate cancer are crucial to address changes in the disease’s behavior.
These advanced treatments provide new opportunities for patients with stage 4 adenocarcinoma of prostate, improving outcomes and quality of life. Ongoing research is advancing approaches, offering hope for a cure. Contact our medical team for a consultation and the best treatment option for you.
| CharacteristicsTherapy type | 2-Year Survival Rate | Response Rate | Duration | Side Effects |
|---|---|---|---|---|
| Standard Treatment | ~25% for advanced cancer | Less than 10% | Several cycles | Severe (nausea, fatigue, hair loss, immunosuppression, skin irritation) |
| Innovative Methods | ~60% for advanced cancer | 45-65% | Up to 4 sessions | Mild (localized discomfort) |
*Data depends on the stage of the disease
A Medical Journey: Every Step of the Way With Booking Health
Finding the best treatment strategy for your own clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized innovative treatment options.
In order to make an informed choice and get a personalized cancer management plan, which will be tailored to your own specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex cancer management programs in each individual case. As a reputable company, Booking Health offers personalized stage 4 prostate cancer treatment plans with direct clinic booking and full support at every stage — from organizational processes to assistance during treatment. We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding them to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets.
- A personal coordinator and interpreter with 24/7 support.
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and reputation. Booking Health is a trustworthy partner, who assists you on the way of pursuing stronger health and better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods for metastatic prostate cancer with leading specialists in this field.
Every Patient Has a Story: Booking Health Treatment Journeys that Inspire
Frequently Asked Questions of Our Patients About Stage 4 Prostate Cancer Treatment
Send request for treatmentStage 4B prostate cancer is the same term as metastatic prostatic adenocarcinoma. The verification of the diagnosis needs visualization – CT scan, MRI etc.
Adenocarcinoma of the prostate is one of the known types of prostate cancer. It is the most common type in any age due to its glandular origin.
Gleason score, PSA level, tumor staging, genetic features, etc., determine the aggressiveness of the tumor. In some cases, adenocarcinoma grows slowly, and in others, it metastasizes rapidly – your healthcare provider elaborates a personal treatment plan to address your tumor’s level of aggressiveness.
In the complex treatment, doctors may use hormone therapy, chemotherapy, targeted therapy, etc. Innovative methods – like Lutetium-177 PSMA therapy and dendritic cell vaccination – and interventional radiology procedures are also used for advanced adenocarcinoma. Surgery is considered in selected men.
In stage 4, disease spreads beyond the prostate – to nearby tissues (4A) or distant organs (4B). The diagnosis of prostate cancer can be verified by PSA test, biopsy, and imaging test – CT, MRI, bone scan. There are other tests that will be recommended in another clinical case.
In different men, symptoms may be mild or severe. Bone pain, difficulty urinating, fatigue, weight loss, swelling in the legs, and general weakness can accompany PCa.
Your healthcare provider will explain personal survival expectancy. The 5-year survival rate for Stage 4 is approximately 30%, with higher rates in cases confined to nearby structures (Stage 4A).
The final scheme is elaborated individually. Options that doctors use actively include hormone therapy, cytotoxic chemotherapy, immunotherapy, targeted therapy, radiation therapy, and palliative care.
It can usually only be controlled. The aim of doctors is the relief of symptoms and improvement of the quality of life.
It reduces or blocks testosterone. That causes the tumor to grow less as it is androgen-dependent. It is the first-line treatment for metastatic prostate cancer.
To be realistic, it is not curative. Chemotherapy reduces symptoms and improves survival, which makes it a valuable method in complex schemes, that are applied in advanced cases.
Typical side effects include fatigue, nausea, weakened bones, hormone-related effects (like hot flashes), and increased osteoporosis and infection risk. Newer options – dendritic cell vaccination – cause only mild adverse effects.
Cancer cells travel via the bloodstream or lymphatic system. They settle in bones, lungs, or liver and that requires additional medical attention and interventions.
Staging 4A involves local spread to nearby structures or lymph nodes. And Stage 4B is about distant metastases.
Palliative care focuses on relieving pain and managing individual symptoms. It is quite helpful in advanced disease.
Life expectancy varies based on the extent of metastasis and available options for treatment of stage 4 prostate cancer. With advanced care, life expectancy is better.
Many factors, including general health, tumor characteristics, treatment received, and response to treatment, etc. determine that. With today's treatments, outcomes can be significantly improved. Studies have shown a median survival of 2 to 5 years. Others have reported longer periods in some patients.
Stage 4 prostate cancer is generally not considered curable. Instead, treatment focuses on controlling disease progression, symptoms alleviation. Some patients may experience extended remission with advanced therapies.
More personalized treatment options offer more patient benefits. Recent advances include targeted therapies such as PARP inhibitors and innovative immunotherapies. Radioligand therapies and refined chemotherapy regimens also offer new hope.
The 2-year survival rate with standard stage 4 prostate cancer treatments (e.g., hormone therapy, chemo, radiotherapy) is around 25%. On the other hand, with innovative options like dendritic cell immunotherapy, TACE/chemoembolization, electrochemotherapy (ECT), PSMA-targeted radionuclide therapy (Actinium-225, Lutetium-177), or focal ablation (HIFU, cryoablation), programs report rates around 60%.
In stage 4 prostate cancer, standard systemic therapy generally achieves a response rate under 10%. However, innovative approaches (e.g., dendritic cell therapy, ECT, focal thermal/cryoablation, and PSMA-targeted radionuclide therapy) can reach about 45-65%.
Typically, standard regimens for stage 4 prostate cancer involve several chemotherapy and/or hormone-therapy cycles over many months (often with ongoing maintenance). In contrast, innovative modalities (e.g., TACE, focal ablation (HIFU, cryo), ECT, or dendritic cell therapy) are often delivered in up to four sessions, sometimes spaced weeks apart, and may be combined within a multimodal plan.
Standard treatments for stage 4 prostate cancer commonly cause moderate to severe side effects (e.g., fatigue, nausea, hair loss, immunosuppression, skin/urinary/bowel effects). In turn, innovative therapies (e.g., TACE, focal ablation, ECT, dendritic cell immunotherapy, and PSMA-targeted radionuclides) tend to have milder, more localized side effects (e.g., transient discomfort, low-grade fever, injection-site soreness).
Stage 4 prostate cancer management includes standard treatments and innovative methods (such as PSMA-targeted radioligand therapy (lutetium-177, actinium-225), interventional radiology and dendritic cell therapy). Treatment is individualized based on disease burden and patient performance status.
German centers (with experience in advanced prostate cancer and radioligand therapy) provide integrated care. Hospitals capable of combining PSMA-targeted lutetium or actinium therapy, interventional radiology, and dendritic cell therapy can provide tailored treatment plans – according to disease progression and patient condition.
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Bohdan Mykhalniuk. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] TheBMJ. Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. https://www.bmj.com/content/386/bmj-2023-077738
[2] American Cancer Society. Cancer statistics, 2023. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21763
[3] American Cancer Society. https://www.cancer.org/
[4] American Cancer Society. Key Statistics for Prostate Cancer. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
[5] NHS. Treatment-Prostate cancer. https://www.nhs.uk/conditions/prostate-cancer/treatment/
[6] Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
[7] Jiao Ma, Lanying Li, Taiping Liao, Weidong Gong, Chunyin Zhang. Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2022 Feb 3;12:796657. doi: 10.3389/fonc.2022.796657. [DOI] [PMC free article]
Read:
Actinium-225 PSMA Therapy: Revolutionizing Treatment for Metastatic Prostate Cancer
Article menu:
- Standard Treatment for Stage 4 Prostate Cancer
- New Treatment Methods for Stage 4 Prostate Cancer
- Clinics for Stage 4 Prostate Cancer treatment
- Comparative Chart with the Effectiveness of the Listed Methods in Stage 4 Prostate Cancer
- A Medical Journey: Every Step of the Way With Booking Health
- Frequently Asked Questions of Our Patients About Stage 4 Prostate Cancer Treatment
Don't know where to start?
Contact Booking Health
